Hope for Dementia with Lewy Bodies as New Treatment Wins Fast-Track Regulatory Backing
A new investigational medicine for dementia with Lewy bodies has been granted an Innovation Passport by the UK’s Innovative Licensing and Access Pathway (ILAP), offering a fresh source of hope for the tens of thousands of care home residents and families living with this challenging condition.
Dementia with Lewy bodies (DLB) is the second most common form of dementia after Alzheimer’s disease, affecting an estimated 100,000 people in the UK. It accounts for around three in every twenty dementia diagnoses and is known for its complex mix of symptoms, including fluctuating cognition, visual hallucinations, movement difficulties similar to Parkinson’s disease, and disrupted sleep.
For care staff, these symptoms can make DLB one of the most demanding forms of dementia to manage day to day, and treatment options for residents remain extremely limited.
The Innovation Passport, awarded following assessment by the ILAP Selection Panel, recognises the medicine’s potential to address this significant unmet need. It was granted alongside a separate award for a liver cancer treatment, underlining the breadth of conditions the pathway is designed to support.
The ILAP is a joint initiative bringing together the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health Northern Ireland. Its aim is to give developers of genuinely innovative medicines earlier, more joined-up access to regulatory and NHS advice, helping promising treatments reach patients more quickly.
James Pound, MHRA Executive Director for Innovation and Compliance, said the latest awards demonstrated “the breadth and ambition” of the pathway, adding that the ultimate goal was “enabling earlier patient access to innovative new treatments.”
Sarah Knight, Senior Commercial Lead at NHS England, said the awards recognised “promising new medicines in development that have the potential to benefit people living with liver cancer and dementia, who have limited treatment options,” and that the programme was helping fast-track development so that treatments proven safe, effective and good value could reach patients sooner.
Applications for the next round of the ILAP opened on 4 August 2026 and remain open until 4 November 2026, with the MHRA continuing to encourage developers working across all therapeutic areas, including dementia, to come forward.
While it will be some time before any new treatment could become available to residents, care providers and dementia charities alike will welcome any sign of progress in tackling a condition that remains, for many families, one of the most difficult to live with.
